Clik here to view.
BeiGene Provides Regulatory Update on the U.S. Biologics License Application...
CAMBRIDGE, Mass., & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology biotechnology company focused on developing innovative and affordable...
View ArticleClik here to view.
First Patient Dosed in CAN108 (Maralixibat) EMBARK Phase 2 Study in Biliary...
BEIJING & CAMBRIDGE, Mass. CANbridge Pharmaceuticals Inc. (HKEX:1228), a leading China and US-based global biopharmaceutical company committed to the research, development and commercialization...
View ArticleClik here to view.
MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of...
SAN DIEGO & TOKYO MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global...
View ArticleClik here to view.
ENHERTU® Approved in the EU for Patients with HER2 Positive Metastatic Breast...
TOKYO & MUNICH, Germany Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the...
View ArticleClik here to view.
Daiichi Sankyo Confirms that a Texas Court has Entered Judgment on the Jury...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) confirmed today that the U.S. District Court for the Eastern District of Texas has entered judgment...
View ArticleClik here to view.
DS-7300 Phase 2 Trial Initiated in Patients with Pretreated Extensive-Stage...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo (TSE: 4568) announced today that the first patient has been dosed in a global phase 2 trial evaluating the efficacy and safety of DS-7300 in patients...
View ArticleClik here to view.
First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1/2 Trial for...
BEIJING & CAMBRIDGE, Mass. CANbridge Pharmaceuticals Inc. (HKEX:1228), a China and US-based global biopharmaceutical company committed to the research, development and commercialization of...
View ArticleClik here to view.
Cell and Gene Therapy Industry Comes Together for Matica Bio’s New Global Event
COLLEGE STATION, Texas Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene...
View ArticleClik here to view.
InnoCare Announces First Prescription of Tafasitamab in Combination with...
BEIJING InnoCare (HKEX: 09969) today announced that tafasitamab (Minjuvi®) in combination with lenalidomide has been approved by the Health Commission and Medical Products Administration of Hainan...
View ArticleClik here to view.
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have received notification of acceptance by the U.S. Food and Drug Administration (FDA) of the...
View ArticleClik here to view.
Enzychem Lifesciences Announces Poster Presentation of EC-18 at the Radiation...
ENGLEWOOD CLIFFS, N.J. Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced today the acceptance of a poster presentation at the Radiation Research Society (RRS)...
View ArticleClik here to view.
Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab...
BOTHELL, Wash. & TOKYO Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive topline results from the phase...
View ArticleClik here to view.
Prestige Biopharma and Intas Pharmaceuticals Announce Partnership to...
SINGAPORE Prestige Biopharma Limited (KRX: 950210, hereafter referred to as “Prestige”) and Intas Pharmaceuticals Limited (hereafter referred to as “Intas”) today announced that the two companies...
View ArticleClik here to view.
武田薬品工業：2022年度第1四半期は力強い業績を達成、通期マネジメントガイダンスの達成に向けて順調に進捗
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE：4502/NYSE：TAK）は、本日、2022年度第1四半期の業績を公表しましたのでお知らせします。当第1四半期は力強い業績を達成し、通期マネジメントガイダンスの達成に向けて順調に進捗しています。...
View ArticleClik here to view.
Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards...
OSAKA, Japan Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the first quarter of fiscal year 2022 (period ended June 30, 2022) and is on track to meet its full-year...
View ArticleClik here to view.
PCIファーマ・サービシズが、がん治療薬をサポートする高薬理活性物質の世界的製造サービスに対する需要拡大に対応すべく、数百万ドルを投じた英国製造施設の拡張を発表
フィラデルフィア （ビジネスワイヤ） — 世界一流の医薬品開発製造受託機関（CDMO）であるPCIファーマ・サービシズ（PCI）は本日、強力ながん標的治療薬の市場成長に迅速対応できるよう、英国ウェールズのトレデガーにある世界クラスの当社施設を大幅に拡張すると発表しました。...
View ArticleClik here to view.
PCI Pharma Services宣布斥资数百万美元扩建英国制造设施，以满足市场对支持肿瘤治疗的全球高效药制造服务日益增长的需求
费城 (美国商业资讯)–全球领先的合同开发与制造组织(CDMO) PCI Pharma Services (PCI)今天宣布，公司对位于英国威尔士特雷迪加(Tredegar)的世界级工厂进行重大扩建，旨在跟上强效靶向肿瘤疗法的市场增长速度。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
武田公司2022财年第一季度业绩强劲；正稳步实现全年的管理层指引目标
日本大阪 (美国商业资讯)–武田(Takeda, TOKYO:4502/NYSE:TAK)今天公布了2022财年第一季度（截至2022年6月30日）的强劲财务业绩，正稳步实现其全年的管理层指引目标。...
View ArticleClik here to view.
InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 JH2...
BEIJING InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in...
View ArticleClik here to view.
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for...
GUANGZHOU, China Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical study evaluating BAT8009, an antibody...
View Article